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ABSTRACT 
 
 
  
 This project attempts to provide updated information on the ongoing research of 
transgenic animals, and discusses the impact of this technology on society.  The project begins 
by describing the main methods used in making transgenic animals, and then provides examples 
of these animals and their various classifications.  Transgenic technology’s many ethical and 
legal issues are discussed as the project progresses.  The authors conclude that this technology 
provides many medical benefits to society, and it should be continued with strong legislative 
oversight.  Millions of lives can be saved by advances in this field.  
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PROJECT OBJECTIVES 
 
 
The purpose of this IQP is to research the technology of transgenic animals and describe 
its impact on society.  In chapter 1, the main methods of creating and screening transgenic 
animals are described.  Because there are currently so many transgenic animals, their main 
groups are discussed in chapter 2, and key examples are provided.  Chapters 3 and 4 depict the 
important ethical and legal issues, respectively, of transgenic technology.  Special attention is 
paid to presenting both sides of an ethical argument, prior to making the final author conclusions.  
In chapter 4, the important Oncomouse court case is discussed, while investigating the pros and 
cons of animal patenting. 
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Chapter-1:  Transgenic Animal Technology 
Randal Bemis 
 
The purpose of this chapter is to explain what transgenic animals are, the methods used to 
create them, and the screening processes used to identify transgenic positives.  For each 
procedure, alternate methods can be used, and this chapter will aim to present the approaches 
used by scientists today.  
 
What is a Transgenic Animal? 
A transgenic animal is one that carries a foreign gene deliberately inserted into its 
genome.  This technology is used to incorporate DNA that has never existed in these animals 
before, to give the animal new properties that did not exist in nature.  The applications and their 
benefit to society are widespread.  DNA that encodes protein-based medicines or nutrients is 
being incorporated into cows and goats, which then secrete these proteins in their milk. Other 
animals are given DNA that will make them grow faster, to make aqua-farming more efficient. 
Some transgenic animals have DNA that allows them to mimic aspects of human diseases, 
giving scientists the ability to study the disease process and potentially screen treatments.  
 
Making the Transgene 
The newly inserted gene is constructed using recombinant DNA (rDNA) methodology.  
DNA, the molecule of life, carries information that dictates the properties of living things.  
Scientists have learned how to isolate DNA, characterize it, excise it, and recombine it, and seal 
it into other DNAs.  Along with the transgene that is intended to be expressed, the inserted DNA 
often includes other vector sequences (plasmid or virus) that enable it to be incorporated into the 
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DNA of the host cell.  The construct also includes a promoter that controls which tissue the 
transgene is expressed in (Transgenic Animals, 2011).  
When making rDNA, the DNA molecules from two or more sources are recombined to 
create a single functioning piece of DNA.  Using restriction endonucleases, the two desired DNA 
strands are cut, leave a short overhang that makes the DNA ends compatible with similarly cut 
DNA.  DNA ligases are then used to covalently bond the annealed fragments to each other, 
forming a single DNA molecule that contains the desired information to be injected into the 
transgenic animal (Recombinant DNA, 2011).  In order for the DNA to be transcribed in the 
correct tissue, it must have a promoter (Figure-1).   The DNA also sometimes includes an 
enhancer sequence that increases the amount of transcription from the transgene.  RNA 
polymerase II, the enzyme that synthesizes RNA from the transgene, binds to the strand of DNA 
at the start site where the DNA begins to be read and is transcribed into RNA. The basal 
promoter is located within about 40 base pairs upstream of the start site. It is usually composed 
of seven base pairs, TATAAAA, and is referred to as the TATA box. Transcription factors 
(labeled red in figure 1) bind to the TATA box to help control the rate of transcription. Another 
promoter, the upstream promoter, is located over 200 base pairs upstream of the start site.  The 
upstream promoter helps control tissue specific expression, while the TATA box controls basal 
transcription.  Both promoters are required for correct transcription (Gene Regulation, 2011). 
The enhancer can be located upstream, downstream, or within the gene that they control.  The 
enhancer binds to transcription factors on the promoter, increasing the speed of transcription 
(Gene Regulation, 2011).  
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Once the desired DNA sequence has been constructed, it is inserted into vector DNA 
(plasmid or virus) so it can be amplified and inserted into animal cells.  The vectors sometimes 
contain antibiotic-resistance genes to allow cells containing the DNA to be selected in media 
containing the antibiotic.  Once the DNA has been inserted inside an animal cell, by infection 
when using viruses, or transfection or though electroporation when using plasmids, the vector 
incorporates into the host genome, and depending on the site of integration hopefully is 
expressed (Recombinant DNA, 2011).  
 
Creating a Transgenic Animal 
 Multiple methods exist for creating an animal containing foreign DNA.  The two most 
common techniques are pro-nuclear manipulation and manipulation of embryonic stem cells.  
Each method has its pros and cons, and is chosen to fulfill specific needs. 
 
Pro-nuclear Manipulation  
 The most common and reliable technique for creating a transgenic animal is 
microinjection of DNA into the pro-nucleus of a newly fertilized egg (Figure-2).  The first step 
in this procedure is to perform in vitro fertilization (IVF) to create a newly fertilized egg.  An 
egg is harvested from a female and fertilized in vitro. After the sperm has entered the egg, but 
Figure-1:  Diagram of Gene 
Enhancer and Promoter 
Sequences.  These DNA domains 
act to help facilitate the expression 
of the transgene.  (Gene 
Regulation, 2011) 
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before the male and female pro-nuclei have fused, the male pro-nucleus is injected with the 
vector DNA containing the transgene. The male pro-nucleus is injected most often because of its 
larger size and short distance from the surface of the egg.  To prevent damaging the newly 
formed zygote, a micro-pipette with a diameter as small as 2 micrometers is used to penetrate the 
cell membrane and enter the pro-nucleus. After the injection, the embryo is implanted into the 
uterine wall of a female of the same species. 
 
 
 
 
 
 
 
 
 
 
 
 The animal that develops is called the founder.  Because the DNA was injected prior to 
the first cell division, all cells of the animal’s body should contain a copy of the transgene.  If 
this animal’s germ cells contain the transgene, each descendent of the founder will be transgenic 
(Cartage.org, 2011). 
 The disadvantage of this technique is the integration of the vector into the animal’s 
genome is random with regards to the location on the chromosome. The location of the transgene 
Figure-2:  Diagram of Pro-nuclear 
Manipulation to Create a Transgenic 
Animal.  The male pro-nucleus (blue) in 
the newly fertilized egg is injected with a 
DNA vector containing the transgene, 
and the completed zygote is implanted 
onto the uterine walls of surrogate female 
mouse (Walinski, 2004). 
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strongly affects transgene expression. So even when a litter of mice were all treated with the 
same transgenic DNA, The DNA will most likely be expressed differently in each cell.  Another 
problem of random integration occurs when the DNA incorporates into the middle of an already 
functioning host gene, which can be harmless or fatal. Although it is not the aim of the science, 
when a transgene integrates and has a noticeable defect, the location of the transgene can help us 
learn where certain genes are and what they control.  The visible defects help scientists map the 
pre-existing genes and understand the organs or tissues they affect (Cartage.org, 2011). 
 Even after a successful founder animal has been created, it is not a true homozygote 
because the DNA has only integrated onto one half of a chromosome. This means that if 
reproduced with a normal animal, the transgene may not be passed on to some offspring. 
Because of this, the founder is called hemizygous. To produce a homozygous animal for the 
transgene, two hemizygous founders are mated to produce a homozygous animal with the 
transgene located on both sides of a chromosome, making all offspring contain the transgene 
(Cartage.org, 2011). 
 
Embryonic Stem Cell Manipulation 
 The manipulation of embryonic stem (ES) cells is an alternate method of 
incorporating foreign DNA into an animal.  In comparison to pro-nuclear manipulation, ES cell 
manipulation targets the animal later in its development, specifically in its blastocyst stage, so 
not all cells of the founder contain the transgene.  To begin the process, an embryo is created by 
IVF, and grown from 5-6 days to the blastocyst stage from which ES cells are obtained from the 
inner cell mass.  The ES cells are placed in culture, and exposed to the transgene DNA.  The 
treated ES cells are then implanted into the inner cell mass of another blastocyst, which is then 
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implanted into the uterus of a foster mother, as before.  Typically, the foster mother is mated 
with a vasectomized male to stimulate hormone secretion and prepare the mother for pregnancy, 
making its uterus more receptive (Transgenic Animals, 2011).  
The advantage of ES cell manipulation is it allows targeted integration by homologous 
recombination.  In this process, the transgene construct contains significant regions of host DNA 
known to flank the desired integration site.  During cell division and the cell cycle, the host DNA 
in the construct recombines with the equivalent host chromosomal DNA, exchanging with it, 
giving the new DNA its desired location (in an active region).  
A second advantage to the ES cell method is it allows for treated ES cells to be selected 
in culture if they contain the transgene DNA, prior to implantation of the ES cells into the inner 
cell mass of the blastocyst.  To screen for these “positive” cells, the transgene vectors contain 
genes that alter the way the cells react to certain drugs (Transgenic Animals, 2011).  For 
example, a vector inserted into a mouse ES cell might contain neo
r
 and thymidine kinase (TK) 
(Figure-3). Neo
r
 encodes an enzyme that inactivates the antibiotic neomycin (a chemical similar 
to the drug G418) which kills mammalian cells. TK encodes thymidine kinase which 
phosphorylates the nucleoside analog ganciclovir, allowing its insertion into DNA, killing the 
cell (Transgenic Animals, 2011).  To screen the ES cells for the desired construct integrated by 
homologous recombination, the cultured cells are exposed to G418. The cells that failed to 
incorporate the vector are killed by the G418. Cells that integrated randomly are also killed when 
exposed to ganciclovir because the TK is expresses. The only cells left in the culture contain the 
desired genes and neo
r
, which incorporated the transgene through homologous recombination 
(Transgenic Animals, 2011).  
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If the blastocysts develop into living pups, they are tested for the transgene. Only a small 
percentage of the pups will test positive and of those, all of them will be heterozygous for the 
transgene.  In addition, since the engineered ES cells represent only a minority of the ES cells 
present in the implanted blastocyst, the animals are chimeric, with some tissues containing the 
transgene and others not.  The heterozygotes are mated, and about one quarter of their offspring 
will test positive as homozygous for the transgene (Transgenic Animals, 2011).  
 
Knock-out and Knock-in Mice 
A common use for targeted integration with ES cell manipulation is creating knock-in 
and knockout mice.  If the desired gene integrated in ES cell manipulation accomplishes 
homologous recombination, and following subsequent breeding to create homozygous animals, 
Figure-3:  Diagram of Targeted Gene Insertion by 
Homologous Recombination.  In the vector (center), the 
desired gene (A* red) and neo
r
 (Green) exist inside the region 
of homology (blue). On top is the desired outcome where A* is 
incorporated at the correct location on the chromosome, and 
botton is an example of random incorporation, placing TK on 
the chromosome outside the region of homology (Transgenic 
Animals, 2011). 
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all cells will have the new transgene instead of the original target gene. In knock-out mice, this 
targeted gene is now non-functioning. This is useful in discovering what a certain gene does.  It 
can teach us whether some genes are redundant.  It can also reveal whether the gene is 
pleiotropic, meaning expressed in different ways depending on the tissue or stage in development 
(Transgenic Animals, 2011).  For example, if a gene knockout has no effect early in development 
but does late in development, the gene likely is expressed late in development. 
To help facilitate when a gene becomes knocked out during development, scientists 
developed the Cre/loxP system.  A virus that normally infects bacteria, called P1, codes for an 
enzyme called Cre recombinase. Cre cuts DNA at LoxP sites.  So if the target gene to be 
knocked out is flanked by LoxP sites (floxed), when Cre is expressed in those cells the gene is 
excised (knocked out).  The Cre gene is attached to a promoter that ensures its expression in the 
tissue of interest, and only in that tissue does the targeted gene get knocked out.  (Transgenic 
Animals, 2011).  
The Cre/loxP process can also be used to a gain in function. Some genes are not 
transcribed in certain tissues because other genes suppress them.  So the Cre/loxP system can be 
used to knock out the repressing gene, allowing the target gene to be expressed.  Investigators 
also create knock-in mice by replacing an existing gene with genes they wish to observe under 
the control of strong promoters (Transgenic Animals, 2011).  
  
Screening Transgenic Animals 
 The production of transgenic animals is not efficient.  In the production of a single 
transgenic animal line, vast numbers of embryos are created to find one pup that has taken up the 
transgene in the desired way.  Though some transgenic animals can be visibly distinguished, the 
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majority look like any other member of their species. To make sure the newly bred pups have 
incorporated a transgene into their genome correctly, they must undergo a screening process. 
Today’s scientists use Southern blot tests or polymerase chain reaction (PCR) analysis to see if 
pups have incorporated the transgene. 
 
Southern Blot Tests 
 Using gel electrophoresis and radioactivity, Edwin M. Southern developed the first 
technique used to sequence DNA, the Southern blot test (Southern, 1975).  A Southern blot 
begins by isolating a sample of DNA from the animal by washing the nuclei in detergents or 
applying pressure to mechanically force the DNA from the nucleus (DNA Extraction, 2011). 
Restriction enzymes are used to cut the DNA into fragments of different lengths.  These 
fragments are sorted by length using gel electrophoresis; the fragmented sample is loaded onto 
an agarose gel and an electrical current is run through it by placing a negative and positive 
charge on opposite sides of the gel. The DNA has a slight negative charge, attracting it to the 
positive charged side of the gel. Because the smaller pieces of DNA have less resistance in the 
gel, they move faster, ending up closer to the positively charged side.  Following electrophoresis, 
the DNA fragment pattern is blotted to a membrane and fixed into place.  The membrane is then 
hybridized to a radioactive single-stranded transgene DNA probe, which hybridizes to the 
transgene DNA fragment on the membrane if present.  The radioactive probe is then identified 
using x-ray film (Vierstraete, 1999). 
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Polymerase Chain Reaction (PCR) Analysis 
 Similar to a Southern blot test, PCR begins with purification of the animals DNA.  Then 
the DNA is placed in a solution containing Taq polymerase and short DNA primers that are 
complementary to the transgene. The solution is heated to denature the template DNA and then 
the solution is cooled, allowing the primers to attach to the ends of the transgene if present. The 
solution is then heated to allow the Taq polymerase to replicate the DNA, starting at the primer 
sites. This cycle of raising and lowering the temperature is repeated to create millions of copies 
of the transgene (Brinton and Lieberman, 1999).  With a large number of amplified copies, the 
transgene DNA can be seen in a gel as a thick band (Figure-4). The transgene amplified by PCR 
should move through the gel at the same rate as the known transgene, appearing as lines in the 
gel with equal distances from the gel origin (The PCR, 2004). 
 
 
 
 
 
 
 
 
 Sometimes a variation on PCR, termed RT-PCR is used to assay expression of the 
transgene.  This technique is similar to PCR but amplifies a signal from cellular RNA instead of 
DNA.  Once the transgene’s correct incorporation into the animal’s genome and its expression 
Figure-4:  Example Gel Electrophoresis After 
PCR.  The ladder on the left in lane-1 is a size 
marker.  The strong bands in lanes 2-4 represent 
amplicons, successful PCR reactions.  Lane-5 
shows a negative PCR reaction (DNA Extraction, 
2011).  
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has been confirmed, it is ready to be mated to begin a transgenic line that will be used in any 
number of biological areas where transgenics are used today.  
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Chapter-2:  Transgenic Applications 
Woo Chan Jo 
 
 The purpose of this chapter is to investigate the types of transgenic animals created to 
date.   Because transgenic technology is very important medically and biologically, thousands of 
different animals have been created, so this chapter will group the animals into categories, 
providing examples within each category. 
 
Disease Models 
 Disease models are transgenic animals engineered to mimic specific aspects of human 
diseases to allow their use for developing vaccines or treatments.  These models rarely mimic the 
full symptoms of the human disease, but still allow therapies to be tested against key disease 
processes. 
 
AIDS Mouse 
 AIDS (Acquired Immune Deficiency Syndrome) is an immune disorder caused by the 
HIV virus.  As is typical of most retroviruses, the initial infection is often accompanied by a long 
lag period in which the virus is barely detectable in the blood, so there can be a long lag time 
before HIV causes severe symptoms.  Only in the end stages of infection, as the immune system 
becomes severely weakened, is the the person considered to fully have AIDS (Avert, 2011). 
Most animals do not get AIDS and are not capable of infection with HIV.  Some 
monkeys can be infected with simian immunodeficiency virus (SIV) and have served for years as 
models for studying how that retrovirus infects the body.  But scientists need additional animal 
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models for studying HIV infection and for screening potential drugs.  AIDS mouse is a 
transgenic animal engineered to express HIV proteins.  HIV cannot normally infect mice because 
they lack CD4 and CCR5 co-receptors on their cell surfaces that HIV binds to cause infection.  
But mice can be engineered to contain the entire HIV genome and to express it.  Malcolm A. 
Martin, Abner L. Notkins, Jan W. Abramczuk and their colleagues at the National Institutes of 
Health (NIH) in Bethesda, injected copies of the entire HIV genome into newly fertilized mouse 
eggs. The eggs were then implanted into surrogate-mother mice. These embryos developed 
normally and contained the HIV genome in all their dividing cells. Following birth, none of the 
first-generation transgenic mice showed any symptoms, but surprisingly after they were mated 
with normal lab mice, some of their offspring showed AIDS-like symptoms, including skin 
disease resembling psoriasis, pneumonia, and lymphadenopathy.  This HIV mouse line has been 
used for studying the disease, especially the causes of the skin disease and lymphadenopathy 
(Weiss, 1988).  
A different type of AIDS mouse was created without the use of transgenic technology by 
Dr. J. Victor Garcia.  In this model SCID mice lacking an immune system were implanted with 
human fetal liver and thymus tissue, which contain the proper combination of receptors to be 
infected by HIV, and which can form portions of a human immune system.  The human tissue 
implants were not rejected because of the faulty immune system.  Then the mice were infected 
with HIV through rectal transmission.  The results indicated that six of seven transplant mice 
showed signs of HIV infection, and three out of four produced antibodies against HIV (from 
thymus cells).  Upon autopsy, HIV was found to be present in the lymph nodes, spleen, other 
immune tissues, lungs, intestines, and the male and female reproductive tracts (Ambrose, 2007).  
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Alzheimer’s Mice 
 Alzheimer’s disease (AD) is a type of dementia caused by neuro-degeneration. AD is a 
progressive disorder that worsens over time, affecting memory, thinking, and behavior (PubMed 
Health 2011a).  AD is caused by the improper processing of amyloid precursor protein (APP) on 
the surface of neurons and glial cells to produce a short peptide fragment amyloid-beta (Aβ) that 
is highly neurotoxic.  The formation of Aβ, or the brain’s inability to get rid of it, appears to be 
the main cause of AD (Access Excellence, n.d.).  In some early-onset cases, AD is genetic, with 
some families having a mutation in the APP gene that increases the rate of Aβ formation.  
 Animals do not normally get AD.  Occasionally orangutans get AD, but it takes decades 
to see symptoms and they are expensive models.  Alzheimer’s mice were engineered to initiate 
AD by inserting the human gene encoding APP in the mouse genome.  The version of APP used 
in the model mimicked an Indiana family with early-onset AD (the Indiana mutation), and was 
mutagenized by Prof Adams at WPI and his colleagues (Games et al., 1995; King, 1995; Adams, 
2010).  Within the first six months after the birth of these transgenic mice, there were no 
symptoms, then from 6 to 9 months the mice started developing Aβ plaques, damaging nerves 
and synapses (Access Excellence, n.d.).  The first successful AD model (Games et al., 1995) 
resulted from the use of the Indiana APP mutation, used the PDGF-β promoter to drive 
expression of Aβ in the same areas of the brain as for AD patients, and included introns 6-8 to 
allow the production of all three isoforms of APP (Adams, 2010). This model was subsequently 
used by Elan Pharmaceuticals Inc. to create an antibody vaccine to remove Aβ from the brain 
(Schenk et al., 1999).  The vaccinated mice also showed improved behavior (Moran et al., 1995).  
The AD mouse model has been widely used for attempting to find treatments of what is now the 
fourth largest fatal disease in America (King, 1995). 
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Oncomouse 
 Cancer represents the uncontrolled growth of cells in the body.  Normally, cells produced 
in the body multiply for a finite number of divisions then die, but cancerous cells multiply 
uncontrollably without dying (PubMed Health, 2011b).  Mice engineered to initiate tumors can 
serve as useful models for studying cancer formation and for screening anticancer drugs.  
Cancers are sometimes caused by oncogenes, special genes that encode growth factors or signal 
transduction proteins that cause uncontrolled growth.  Placing an oncogene inside the genome of 
mice can cause the animal to develop cancer.    
The first Oncomouse line was created at Harvard University in the early 1980s by Philip 
Leder and his colleagues (Stewart et al., 1984).  This mouse line was engineered to contain the 
human oncogene myc, so the mice develop tumors (Figure-1).  Harvard and Dupont submitted a 
patent on the animal in 1984 (Leder and Stewart, 1984), which was finally granted in 1988 as patent 
number 4,736,866 for the transgenic mouse containing an activated recombinant oncogene in in its 
germ line and somatic cells.  This served as the world’s first patent for an animal (discussed in detail 
in Chapter-3) and noted that the patent did not extend to humans, claiming that such a patent would 
be unethical.  This mouse line is one of the most famous transgenic lines ever created, and serves as a 
model for studying the formation of tumors and for screening drugs to block cancer formation 
(Bioethics and Patent Law, 2006).  Philip Leder, one of the main creators of Oncomouse described 
his invention as something that would help the world study cancer and understand it in greater depth 
(Stern, 2000). 
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Transpharmers 
 Transpharmers are genetically engineered animals that secrete a desired protein drug in 
their blood, eggs, or milk. The preferred place to produce the protein is in milk, because 
secretion of a foreign protein in that location is the least likely to have any physiological effects.  
To accomplish this, the transgene encoding the drug of interest is coupled with a DNA promoter 
that directs production of the drug only in the mammary gland with secretion into the milk 
(Biotechnology Information Series, 1995).  
 
Transpharmer Mice 
 The first transpharmer was a mouse created in 1987 by a group in Framingham, MA.  Its 
purpose was to produce the clot dissolver human tissue plasminogen activator (tPA) in the 
animal’s milk (Gordon et al., 1987).  To accomplish this, the cDNA encoding tPA was coupled 
to a whey acidic protein (WAP) gene promotor.  tPA has a crucial role in dissolving blood clots 
by increasing the breakdown (fibrinolysis) of fibrin-containing blood clots (Abcam, 2011).  So 
this drug is sometimes used to treat heart attack patients to open up clogged heart arteries. 
 
 
Figure-1: Photograph of Oncomouse.   
(Bioethics and Patent Law, 2006) 
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Transpharmer Sheep 
  After the creation of transpharmer mice, the same idea was used for larger animals such 
as sheep, goats, and cows. Using nuclear transfer from fetal fibroblast cells, Schieneke et al. 
(1997) were able to create a transpharmer sheep that produce human clotting factor IX (FIX) in 
their milk. FIX is essential for blood coagulation, and the use of this protein helps some patients 
with the disease hemophilia B. The transgene used to make this sheep included the human FIX 
gene linked with the ovine beta-lactoglobulin gene promoter (so that the production of human 
FIX takes place only in the mammary gland of the sheep).  Using this transgene proved that the 
production of FIX in both transgenic sheep and mice is possible (Schieneke et al., 1997). 
 
Transpharmer Goats 
 Scientists at GTC Therapeutics created a transgenic goat that produces human anti-
thrombin (ATryn®) in the mammary gland which is then secreted into milk (Figure-2).  ATryn 
is a recombinant form of human anti-thrombin, a 
blood thinning protein, and is the first transpharmed 
drug to be approved by the FDA.  ATryn is used in 
peri-operative and peri-partum patients to prevent 
blood clotting.  The transgene used to create these 
goats consists of the human gene encoding anti-
thrombin-III fused with a milk protein promoter 
(ATryn®, 2008). 
 
 
Figure-2: Photograph of a Transgenic Goat 
that Produces Blood Thinning Anti-
Thrombin Protein it its Milk (BBC News, 
2006) 
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Transpharmer Cows 
 The most famous example of transpharmer 
cattle is Herman the Bull (Figure-3).  Herman was 
engineered in the Netherlands to produce lactoferrin, 
a protein with iron that is important for the infant’s 
growth (Biotech Notes, 1994). This bull was created 
in 1991 by Krimpenfort et al, who used gene 
microinjection with a transgene that consisted of 
human lactoferrin cDNA controlled by bovine alpha-S1-casein (Krimpenfort et al., 1991).  
Cow’s milk does not naturally contain lactoferrin, so infants fed mostly cow’s milk have to 
supplement other sources rich in iron.  This experiment creates a new source of cow’s milk rich 
in iron. Although Herman himself did not transpharm Lactoferrin, he became the father of eight 
female calves, and each is able to transpharm lactoferrin (Biotech Notes, 1994).  
 
Xenotransplanters 
 Every day, transplant candidates die waiting to receive organs.  Because of the severe 
shortage of viable organs for transplant, scientists developed the idea of xenotransplantation in 
which organs would be transplanted from animals into humans until human replacement organs 
become available.  Xenotransplanters are transgenic animals specially engineered to produce 
organs histocompatible with humans. 
Because of genomic similarities, primates at one time were thought to be better 
candidates for xenotransplanters than pigs, but this was later proven untrue.  For example, in the 
famous case of Baby Fae, on October 26, 1984, in Loma Linda University Medical Center in 
Figure-3: Picture of Herman the Bull in Naturalis, 
The Museum of the Netherlands (Naturalis, 2004) 
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California, Baby Fae a five pound infant received a xenotransplant of a baboon’s heart into her 
chest (Fabregas, 2006).  Unfortunately, she died after twenty days because her immune system 
rejected the heart.  After this case, the idea of xenotransplantation became very controversial, 
and the topic was not pursued until the advent of transgenesis. 
One of the first transgenic xenotransplanter animals created were pigs lacking the gene 
(knockout) encoding an enzyme that adds the sugar α-1,3-galactose on the organ surface (Lai et 
al., 2002).  The gene knocked out was α-1,3-galactosyltransferase (GGTA1) (Pearson, 2003).  
Without GGTA1, the sugar α-1,3-galactose is not added to the organ surface.  The sugar is 
viewed as foreign by humans, so decreasing its concentration on the pig’s organ surface 
decreases the chance of immune-rejection of the transplanted organ.  These pigs were engineered 
in Blacksburg, Virginia, by Revivicor a biotech firm funded by the University of Pittsburg 
Medical Center (UPMC).  Revivicor is planning on having pig organ centers across United 
States so people on an organ waiting list can have access to the vital organs they need until a 
human organ becomes available.  For further use of these medical wonder pigs, Revivicor is 
developing two projects that seem promising. One application is to use pig islets to boost insulin 
production in patients with type-I diabetes.  A second application is to use pig hearts for patients 
with heart failure rather than using mechanical pumps. Revivicor estimates the market for pig 
organs will eventually be worth about six billion dollars annually (Fabregas, 2006). 
However, there are problems associated with xenotransplantation, including the 
continued need for immune-suppressive drugs, and the danger of virus transmission (Catez, 
2005).  This topic will be discussed in more detail in chapter-3, but for here suffice it to say that 
possible viral transmissions from transplanted organs to recipients could be minimized by pre-
screening the organs for known viruses prior to transplant and by growing the pigs in relatively 
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viral free environments, especially indoors.  However, dangers remain since previously 
uncharacterized viruses might not be detected in a pre-screening. 
 
Transgenic Food Sources 
  The purpose of this category of transgenic animal is to genetically modify animals to 
better satisfy human consumption needs, by increasing growth rates, reducing carcass fat, and 
increasing feed efficiency.  One way to do this is to give the animal a transgene for a growth 
hormone.  This approach has worked well for fish, but not for mammals.  The latter, which 
caused a lot of problems, resulted in the use of the term “frankenfoods”.  
 
Superpig 
 Super pig is a generic term for at least two types of transgenic animals engineered to 
produce extra growth hormone.  The pigs are also known as the Beltsville pigs because they 
were created in a research facility in Beltsville, Maryland.  The first set of swine was engineered 
in 1989 to express bovine growth hormone under the control of a mouse metallothionein 
promoter (Miller et al., 1989).  The metallothionein promoter was chosen because it is always 
on, and does not need to be induced to make its product.  The second set was produced in 1997 
to express ovine growth hormone under the control of an ovine metallothionein promoter.  In 
both cases, the swine grew to very large sizes.  Unfortunately,  the production of excess growth 
hormone produced numerous physiological problems, including kidney and liver problems, 
uncoordinated gait, bulging eyes, thickening skin, gastric ulcers, degenerative joint disease, heart 
disease of various kinds, nephritis, and pneumonia (Rollin, 1996; Horwitz, 1998). Thus, the extra 
growth hormone did not just make big pigs, but also enlarged defective organs and joints (Pursel 
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et al, 1997).  Because of these serious health problems, superpig was euthanized, and scientists 
have placed a voluntary moratorium banning all growth hormone experiments in mammals. 
 
Superfish 
 AquaBounty Technologies, headquartered in Waltham, Massachusetts, is a biotech 
company near to getting FDA approval to sell their genetically engineered (GE) transgenic 
salmon.  If approved, these fish would become the first genetically engineered animals for 
consumption in the world.  These fish, termed AquAdvantage Fish, have been engineered to 
express salmon growth hormone under the control of an eel-like “ocean pout” promoter.  The 
promoter is switched on throughout all stages of salmon development, so these fish grow faster 
than wild type salmon whose growth hormone production occurs only during specific stages of 
development (Figure-4).  The fish appear to be the same as WT fish in all other aspects of 
behavior (Biotechnology Industry Organization, 2006).  The fish are also sterile, which decreases 
worries about cross breeding if the fish happen to escape and breed with wild type salmon. 
 
 
 
 
 
 
 
Figure-4: Growth Curves for Transgenic and Wild Type Salmon.  (Aquabounty 
Technologies, 2009) 
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Biological Models 
 The last category of transgenic animal is Biological Models.  These animals are created 
to test the function of newly discovered genes and their proteins, or to determine whether a new 
species can be made transgenic. 
 
ANDi  the Monkey 
 ANDi, which stands for “inserted DNA” spelled 
backward, is the world’s first transgenic monkey (Chan 
et al., 2001).  This monkey (Figure-5) was created in 
Oregon in Gerald Schatten’s lab to carry the gene for 
green fluorescent protein (GFP) to serve as a marker for 
transgenesis; it did not provide ANDi with any new 
biological property (Vogel, 2001).  Although the 
experiment was a success since ANDi took up the 
transgene, the GFP gene was not expressed into GFP 
protein, which would have fluoresced green.  Anthony Chan, one of the researchers creating 
ANDi said that the ultimate goal of creating such a monkey was to prove that transgenic non-
human primates can be made, and if so, they can eventually be used to make disease models 
closer to humans instead of using mice.  To create ANDi, 224 unfertilized rhesus monkey eggs 
were mixed with a virus containing the GFP gene.  Most of the manipulated eggs failed to 
divide, but 40 of them divided and were chosen at the four-cell stage for implantation into 
surrogate mothers.  These mothers gave birth to three healthy males and two stillborn twins.  Of 
Figure-5:  ANDi the Monkey.  Figure shows 
the world’s first transgenic monkey (Vogel, 
2001). 
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the three healthy males, only one (ANDi) carried the GFP gene (Trivedi, 2001).  
 
Smart Mouse 
  As a scientific model for investigating the function of the protein NR2B, neurobiologist 
Joe Tsein and his colleagues at MIT created a mouse called Doogie (Tang et al., 1999). This 
mouse is known for its ability to retain information and solve mazes. The NR2B transgene 
encodes a subunit of the NMDA brain receptor that predominates when neurons are young.  By 
mimicking young neurons and their ability to make connections, scientists hoped to create a 
mouse with facilitated learning.  Ira Black, Chairman of Neuroscience and Cell Biology at 
Rutgers University believes that the creation of Doogie will eventually lead to such therapy for 
humans to enhance our own memory and learning. “But this is far in the future, and is certainly 
not something we could bring to the bedside tomorrow” (Harmon, 1999).  
 
 
 
 
 
 
 
 
 
Super Mouse 
 The world’s first expressing transgenic animal was created at the University of 
Figure-6:  Doogie the Smartmouse.  This mouse shows superior 
memory and intelligence (BBC News, 1999). 
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Washington and the University of Pennsylvania by Richard Palmiter and Ralph Brinster who 
proved that a gene from one animal could be put into another, making the offspring have the 
transgenic trait (Palmiter et al., 1982).  The so-called Supermouse (Figure-7) contained a rat 
growth hormone gene under the control of a metallothionein promoter (always switched on), so 
the mouse grows to a larger size.  Many of their offspring also carried the trait (Klein, 1995).  
The creation of this mouse proved that transgenic technology was capable of working, and 
opened the door for the thousands of subsequent transgenic animals created.   
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Chapter-3:  Transgenic Ethics 
Randal Bemis 
 
The previous chapters discussed transgenic technology, how the animals are engineered 
and what types have been created to date.  The goal of this chapter is to go beyond the 
technology to explore whether we as a society should be constructing the animals.  Transgenic 
ethics is a balancing act between the benefit to society versus the detriment to the animal.  But 
each category of transgenic animals must be weighed separately, and even specific examples 
within a category must be considered separately.  Not all transgenic applications have negative 
effects on animals, while other experiments can reduce the animals’ quality of life.   
 
Framing the Transgenic Ethics Questions 
 In life, actions do not always reveal a crisp line between right and wrong, but the positive 
effects should hopefully outweigh the negatives.  With transgenics, the outcome may yield cures 
for diseases that were once out of reach, but who is to say that a human’s life is more important 
than the animal lives it took to develop these technologies. Scientists, as well as citizens, must 
look at transgenic technology and weigh the benefits to society against the detriment to the 
animals to decide what is ethically right and wrong.   The positives and negatives of each 
transgenic application are very different from case to case, so they need to be individually 
examined to truly judge if a type of transgenic animal should be produced.  
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Disease Model Ethics 
 A disease model is a transgenic animal that has been altered to allow them to mimic a 
human disease, or portions of a human disease.  These animals are used to aid our understanding 
of the disease process, and to help screen potential cures.  The benefits to society from these test 
subjects can be great, but it gives animals a disease their species has never encountered.  
 Some disease models suffer more than others.  In the case of Oncomice, the mice develop 
tumors which can be painful if allowed to develop to the advanced state.  When the experiment 
requires advanced tumor formation, Animal Care and Use Committees (IACUCs) require the use 
of painkillers.  The American Cancer Society estimates that over ten million Americans suffer 
from cancer, and the prevalence is similar worldwide.  Although no animal’s suffering is a good 
thing, the potential Oncomouse has to help a vast number of people is great.  
Another disease model is Alzheimer’s disease (AD) mouse.  Compared to Oncomouse, 
AD mice show no evidence of suffering, and the memory loss does not appear to affect the 
eating behavior, reproduction, or play of the mice.  AD mice live mostly normal lives, and have 
already aided in the the development of an antibody vaccine that removes the senile plaques 
from the brain that cause Alzheimer’s (Schenk et al., 1999).  
 While many researchers feel that disease models are required for developing therapies, 
some organizations feel that no animal deserves that treatment.  A group called Animal Aid says 
that animals make poor disease models because altering a small number of genes does not make 
them human (Animalaid,  2006). While some disease models are not perfect, and some cannot 
fully simulate a human disease, many have led to advancements in treating diseases like cancer 
and Alzheimer’s (Speaking, 2008). 
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Transpharmer Ethics  
 Transpharmers are engineered to secrete protein-based drugs in their milk, blood, or eggs. 
Transpharmers include mice, sheep, cows and goats, though in most cases drug production 
occurs in large milk producing livestock. Transpharmers are an example of transgenic animals 
that live normal lives. Many transpharmers live on farms like any other dairy animal. The 
mammary glands and milk are not part of the animal’s own life supporting organs, so foreign 
proteins do not have a strong physiological effect on them.  As with the production of all 
transgenic animals, there is a risk of embryo loss when producing a transgenic line. This comes 
from genes sometimes inserting into non-target areas of the genome, leading to developmental 
problems. To help minimize this, researchers have developed a targeted method of transgene 
insertion that uses homologous recombination when treating embryonic stem cells (discussed in 
Chapter-1).  Other researchers are also using adeno-associated viruses (AAV) to increase the 
accuracy of transgene incorporation.  But once a line of transpharmers has been established, the 
production of protein-based drugs is no different than the production of milk (Gillespie, 2011).   
 
Xenotransplanter Ethics 
 People die every day waiting for organ transplants to become available, and in many 
cases a human must die before their organs are available for donation.  With xenotransplanters, 
full organs or cells can be taken from animals and used in humans to help them survive. The 
animals (usually pigs) are engineered to make their organs more immunologically compatible 
with human recipients.  There are inherent risks involved with xenotransplants, such as rejection 
and disease transmission, though many people in need of transplants have very few options. The 
chances of rejection have been reduced using transgenic technology and by using immune 
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suppressive drugs.  And to reduce the chances of disease transmission, donor animals are 
monitored for known viruses and kept in isolated populations to reduce the risk of disease spread 
(Carnell, 2000).  
 Because xenotransplantation incorporates genetically altered tissue into a human, it raises 
similar ethical concerns as patients receiving pig heart valve transplants.  Do these transplants 
make a person less human or somehow change their identity (Correa, 2001)? Though this could 
concern a person in need of a transplant, ultimately it should be the patient’s choice to accept 
treatment.  If the patient feels that receiving a xenotransplant is wrong, they can deny the 
procedure.  
 With respect to the animals themselves, these animals were created to help people. To 
save human lives, the lives of animals are taken.  This is similar to the millions of livestock 
sacrificed annually for the food industry.  Some believe that animal lives hold the same value as 
humans, while others believe that animal lives must be taken to survive. 
  
Transgenic Food Source Ethics 
 Superpig and Superfish are two examples of transgenic animals that contain foreign 
growth hormone genes.  These animals were made with the intention of making meat production 
more efficient.  Superpig was considered a failure, while Superfish may soon be the first 
transgenic food source approved by the FDA.  
 Superpig is a prominent example of a transgenic animal that is not worth producing 
because of the strong negative impact the growth hormone had on the animal, while the model 
provides little benefit to society. Superpig was successful in having faster muscle mass 
production, but depending on the copy number of the growth hormone gene in the animal’s 
 37 
genome, the side effects were severe and unpredictable.  The pigs suffered from kidney and liver 
problems, as well as lethargy, lameness, uncoordinated gait, bulging eyes, thickening skin, 
gastric ulcers, severe synovitis, degenerative joint disease, heart disease of various kinds, 
nephritis, and pneumonia (Rollin, 1996).  Because the animal suffering was very clear, 
researchers voluntarily stopped all projects using growth hormones in mammals, an ethical 
decision, I, the author, appreciate and respect.  
 On the other hand, Superfish was a relative success. AquaBounty Technologies 
developed salmon that grow faster than wild salmon because growth hormones are produced 
during all stages of development instead of seasonally. This was achieved with minimal 
detriment to the animal, with side effects including minor gill irritation and a slightly shorter 
lifespan (Uniqueness, 2002).  If the FDA approves the salmon for human consumption, they will 
change the aqua culture industry forever, being the first genetically engineered meat. This step is 
important to the field transgenic food sources because the demand for faster food production 
grows as the world’s population climbs. 
  
Biological Model Ethics 
Biological models are animals used to discover what certain genes and proteins do in the 
body.  In fact, the world’s first expressing transgenic animal was made just for this purpose, to 
understand the effects of over-expressing growth hormone in mice.  Biological models are 
created so that the over-production or lack of a certain protein can be understood in living 
animals. With a better understanding, these biological models open up new possibilities for 
transgenic applications. Though the methods used to create transgenic animals are not efficient, 
the animals lives used in producing biological models are not wasted.  Learning that a certain 
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gene can hold a negative effect on an animal is valuable. It can prevent future use of certain gene 
classes in animals, and help prevent further animal suffering by genetic disorders related to that 
gene.  
 
Activism and Anti-Transgenic Groups 
 In recent years, transgenic technology has grown, and with it, people’s opinions have 
been formed by different information they hear or read in the media.  Public opinion will affect 
the progression of transgenic technology in the future, thus it is important for the public to 
understand the technology.   
 The American Anti-Vivisection Society (AAVS) advocates the reduction of animal use in 
research, and the use of alternate methods to end animal suffering.  Many of their articles are 
aimed at educating people about the extent of animal testing and what is involved. They aim to 
steer legislation in a direction that will stop animal suffering.  Reducing animal suffering 
whenever possible is something I admire, but many articles only focus on the animal’s health and 
not on the benefits to humans (AAVS.org, 2011). With the pending approval of genetically 
engineered fish for human consumption, the AAVS released an article describing the lives of 
suffering these salmon endure, without mentioning how researchers work to reduce these side 
effects, and they exaggerated the side effects.  The article ends by telling the reader how to 
contact local officials to prevent the FDA from approving the new technology (AAVS.org, 
2011).   
 While the efforts of groups like the AAVS are aimed to protect animals, the methods they 
use if bending the truth, are detrimental to scientific research involving animals. Educating the 
public about these new technologies is important, but needs to involve both sides of the story, 
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including an unbiased view of true side effects and what benefits the animals bring to society. 
The AAVS avoids the positive effects gained from the use of disease models, while dwelling on 
animal suffering without discussing research done to reduce human suffering.  
  
Religious Views on Transgenic Technology 
 With the rise of transgenic technology, some people look to their religion for how they 
should feel about it.  Though no religion is the same, many share similar opinions on the 
treatment of animals.  
 In Christian text, God gave man dominion over animals. This is not to say that man 
should do whatever they choose with them, but man should understand the value of animals and 
use them with respect. The Catholic Church has a vast understanding of the use of animals for 
mankind, and in general is very accepting of it. They make it clear that animals should be used 
for humans primary needs, and with new technologies, the need for animal use can change. The 
Vatican says, “Humans must answer to the Creator for the manner in which they treat animals. 
As a consequence, the sacrifice of animals can be justified only if required to achieve an 
important benefit for man (Correa, 2001).”  This statement is accompanied by the fact that 
unnecessary animal suffering must be prevented, and consideration for the necessity for certain 
applications of genetic engineering must be considered.  
 Buddhist religious beliefs are very different from Christians but reach a similar 
conclusion on animal research. Buddhists believe in karma.  Doing bad things will result in bad 
karma, potentially bringing bad things on themselves. They also believe that all animals deserve 
equal treatment.  In regards to animal experimentation, the researchers must accept that 
experimenting on animals may bring them bad karma. Experiments must also be done with good 
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intentions and only if there is no alternative.  Researchers must also do everything in their power 
to reduce animal suffering and death (Buddhism, 2009). 
 Other world religions, like Judaism and Islam, come to a similar conclusion about animal 
research, recognizing animal studies as important if the intentions are good.  In all of the world’s 
major religions, doing harm to animals is only right if it is to improve the lives of humans.  
 
Author Chapter-3 Conclusions 
 The debate on the morality of transgenic research is large and will continue to exist as 
long as groups promote opposing views on the matter.  This debate is fueled by media opinions, 
and whoever is the most dramatic and outgoing will often stand in the spotlight (Rollin, 1996).  
Thus, it is important when making ethical judgments about transgenic research to base the 
opinion on fact and to keep an open mind.  Transgenic animals are vastly different in their 
benefits to society and their extent of suffering, thus it is important to judge each category (and 
even each specific animal) separately. I agree with opponents that mammalian growth hormone 
experiments were a disaster, and the self-imposed moratorium was the correct mode of action.  
Other applications, like AD mouse or transpharmers, appear to have no observable pain, and so 
far have had strong positive effects on human lives. Some groups believe all harm to animals if 
wrong, and that no transgenic animal is made without risking the animal’s wellbeing.  It is 
important to realize that progress is never made without risks. People take risks every day when 
driving cars or making investments, but without taking risks, the human race could not have 
accomplished all the great things they have today. The right thing to do is not always clear, but if 
researchers do everything in their power to reduce animal suffering, and use transgenic 
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technology with good intentions, then continuing transgenic animal research is the right thing to 
do.  
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Chapter-4: Transgenic Legalities 
Woo Chan Jo 
 
 Up to this point we have discussed the techniques used to create transgenic animals, 
discussed how they are categorized, provided examples within each category, and investigated 
transgenic animal ethics.  This chapter will focus on the legalities of transgenic animals, as an 
example of how society helps regulate complex technology.   We will discuss the landmark 
transgenic court cases such as the world’s first patented animal Oncomouse, both within the U.S. 
and internationally.  The Canadian Oncomouse case is especially important as it concluded that 
life cannot be patented.  We will also discuss the general pros and cons of patenting animals as 
one of the most debated topics in transgenic animals, and the recent U.S. recommendations on 
how companies should gain FDA approval for their transgenic products.   
 
General History of Patenting 
Patent history goes as far back as medieval times. The very first law gave exclusive rights 
for a limited amount of time to an inventor and was awarded in Venice in 1473.   Later, in 
England, the government granted sovereign rights to monopolies, allowing them to raise money 
without forced taxation (A Brief History of the Patent Law of the United States, 2003).   For 
example, a patent was granted for an invention related to the manufacture of silk.   
Within the U.S., the Federal Patent Act was enacted in 1790 as “An Act to promote the 
Progress of Useful Arts” (A Brief History of the Patent law of the United States, 2003).   The act, 
containing seven sections, empowered the Secretary of State, Secretary of War, or Attorney 
General, allowing any two of the three to grant a patent to an invention for up to fourteen years, 
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as long as the invention was sufficiently useful and important.  The 1790 act was later replaced 
in 1793 by then Secretary of State Thomas Jefferson, who was initially involved with the first 
act. The new act helped define a “patentable invention” as “any new and useful art, machine, 
manufacture, or composition of matter, and any new and useful improvement on any art, 
machine, manufacture or composition of matter”, a definition that remains almost unchanged to 
this day.   The 1793 act was frequently amended over the years to address controversial issues, 
including the patenting of genetically modified animals (A Brief History of the Patent Law of the 
United States, 2003). 
 
Patentable Inventions, 35 U.S. Code 
To grant patents to U.S. inventors, the invention must satisfy three different categories: 
novelty, usefulness, and non-obviousness. The novelty requirement measures the “newness” of 
the invention, so the invention must not already be known to the public more than a year prior to 
the application filing date.  The invention must also be able to perform the intended task and 
satisfy the usefulness requirement.  The last requirement is the non-obviousness, so the invention 
must be “one its kind” and not obvious so any skilled person in the field would have devised the 
same invention.  Furthermore, the 35 U.S. code 101 states “Whoever invents or discovers any 
new and useful process, machine, manufacture, or composition of matter, or any new and useful 
improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of 
this title”.  So the terms “manufacture” and “composition of matter” must be interpreted when 
attempting to patent life (Bitlaw, 2000). 
A patent granted by the U.S. Patent and Trademark Office (PTO) gives rights to the 
inventor.  These rights exclude others from manufacturing or commercializing the patented 
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product usually for 20 years from the date of application.  A patent owner can sell the product or 
charge others for its use (Bitlaw, 2000). 
 
First Patent on Life:  Diamond vs. Chakrabarty 
 The first patent on a living organism was not an easy trial.  The landmark case involved 
the engineering of a Pseudomonas bacterium to allow it to breakdown oil.  In 1972, 
microbiologist Ananda M. Chakrabarty applied for a patent for his invention of a genetically 
modified bacterium. However, the U.S. examiner initially rejected the patent, claiming that 
micro-organisms are “products of nature” and are not a “composition of matter”.    
Chakrabarty appealed the case to the U.S. Supreme Court, making the landmark case of 
“Diamond vs. Chakkrabarty (1980).  The Supreme Court eventually found the invention met all 
requirements of the 35 U.S.C. 101, so found the microorganism to be a patentable subject matter.  
The court took into account the definition of manufacture in 35 U.S.C. 101 from the dictionary 
as: “the production of articles for use from raw materials prepared by giving to these materials 
new forms, qualities, properties, or combinations, whether by hand labor or by machinery.” The 
court gave expansive meaning to terms such as “manufacture” and “composition of matter” 
adding an even more comprehensive “any manufacture or composition of matter”.  
Chakrabarty’s microbe was novel (no one had made an oil eating bacterium before), useful (it 
could be used to treat oil spills) (Figure-1), non-obvious (other genetic engineers had not come 
up with the idea), and was a new manufacture or composition of matter (which the Supreme 
Court liberally applied to include engineered living organisms).  By allowing the patenting of a 
microbe, the Supreme Court opened the door to the eventual patenting of engineered animals 
(Diamond v Chakrabarty, 1980). 
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First Animal Patent:  Oncomouse 
The first animal patent was granted for a mouse termed “Oncomouse” (for its ability to 
serve as a cancer disease model).  The mouse is also known as the “Harvard mouse” because it 
was invented by Harvard researcher Philip Leder and his collaborators at Dupont 
Pharmaceuticals (Figure-2) (Stewart et al., 1984).  The original Oncomouse contained the native 
mouse c-myc oncogene under control of a mammary tumor viral promoter, which increased 
expression of the c-myc oncogene in mammary tissue resulting in mammary tumors (Stewart et 
al., 1984).  Later versions of the mouse contained the human ras gene which makes it more 
susceptible to cancer than wild-type mice (Anderson, 1988).  
The original patent was filed in 1984 in the United States Patent and Trade Office (Leder 
and Steward, 1984) for a “transgenic non-human mammal containing a recombinant activated 
oncogene”.  That patent was eventually awarded in 1988 as patent #4,736,866.  A subsequent 
Figure-1:  Oil Spill at Mouillie Point.  
This oil spill accident allowed 
Chakrabarty’s microorganism to meet 
the patenting usefulness  requirement 
of 35 U.S.C. 101.  (Richardson,  2000). 
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patent was filed in 1992 (Leder and Stewart, 1992) for a method for producing a cell line from a 
transgenic non-human mammal, which was awarded as patent #5,087,571.  A third patent was 
filed in 1999 (Leder and Stewart, 1999) for a method for testing mice containing oncogenes, 
which was awarded as patent #5,925,803.  These broad patents gave DuPont the right to oppose 
any entity attempting to use any non-human mammals containing oncogene sequences.   
 
 
 
 
 
 
The patents were very controversial, because for the first time it gave ownership of an 
animal and its offspring to a company who would control its selling and distribution.   
DuPont had ownership, and anyone who wished to use the mice for any purposes needed their 
permission.  Initially, DuPont charged very high fees for using the mice, which some researchers 
argued hindered cancer research rather than stimulate it, because only the wealthy labs could 
afford to work with the mice.  Eventually, DuPont and the National Institutes of Health (NIH) 
made an agreement to give free access to the mice for non-profit researchers, with companies 
still paying a small usage fee, and DuPont still required licences for anyone using the mice, and 
had limits on their breeding and distribution.  In 1998, Dupont sublicensed the patent to Tactonic 
Labs, so Tactonic is able to provide Oncomice worldwide for others to research oncology, study 
tumor progression, or screen drugs for anti-cancer effects (Tactonic, 1998).  Now that Oncomice 
are more accessible, there is hope to finding new approaches for treating cancer (Smaglik, 2000). 
Figure-2: Dupont Logo.  This company was 
awarded ownership of the “Harvard mouse” 
and is licensed to provide Oncomice for 
either non-profit or commercial uses 
(Google.com, 2011). 
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Oncomouse Case in Europe 
 The Oncomouse patent was not filed just in the United States.  The European application 
was filed on June 22
nd
 1984 (Sharples and Curley, 2011).  The patent was initially rejected by 
examiners in Munich in 1989 on three grounds:  First, patents on plants and animals were 
forbidden by article 53(b) of the European Patent Convention (EPC).  Secondly, the discovery is 
not reproducible.  Third, European patent law does not solve the moral and ethical issues of 
transgenic animals (Dickman, 1990).   
Dupont appealed the rejection, and the Technical Board of Appeal eventually allowed the 
European patent.  The technical board stated that while article 53(b) of EPC excludes the 
patenting of animal varieties, article 52(1) states that patents are available for inventions capable 
of industrial application. So the technical board argued that because Oncomice had commercial 
applications they were patentable.  Second, with respect to non-patentable “animal varieties” in 
53(b), the board concluded that genetically altered animals like Oncomouse did not constitute 
“animal varieties”, so they were not excluded for patenting by the wording of article 53(b).  
Finally, the technical board concluded that due to the societal benefits that Oncomice can 
provide, their invention overrides the ethical issue clause of Article 53(a) which states that 
European patents will not be granted to inventions contrary to morality.  The Board of Appeal 
can give an exception to specific inventions, and in the Oncomouse case although the mice can 
suffer if experimenters allow advanced tumor formation, the examiners argued their benefits 
allowed the exception.  They argued Oncomice have “outweighing benefits to mankind”, so the 
European Oncomouse patent was awarded (Sharples and Curley, 2011).  One significant 
difference between the US and European Oncomouse patents is the EPO restricted the patent to 
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rodents containing oncogenes in 2001, and to mice in 2004, rather than giving ownership to all 
non-human mammals as in the US case (Cyranoski, 2004). 
 
Oncomouse Patent Denied in Canada 
The Canadian Oncomouse patent was filed in June 1985 in the Canadian Intellectual 
Property Office, but Canada has a strict rule against giving patents for higher forms of life, so did 
not award the patent.  Harvard then requested an appeal to the Commissioner of Patents who also 
denied the patent on the grounds that a transgenic animal cannot be considered an invention 
according to the Canada Patents Act (Mitchell and Somerville, 2002).  Harvard appealed a 
second time in 1998, but the denial was upheld by the Canadian Federal Court Trial Division, 
who stated: 
“On even the broadest of interpretation I cannot find that a mouse is “raw 
material” which was given new qualities from the inventor. Certainly the presence 
of the myc gene is new, but the mouse is not new, nor is it “raw material” in the 
ordinary sense of that phrase… A complex life form does not fit within the 
current parameters of the Patent Act without stretching the meaning of the words 
to their breaking point, which I am not prepared to do”, said judge Nadon while 
denying a patent protection for the Oncomouse (Mitchell and Somerville, 2002). 
 
 
In September 1999, after having made a firm decision to reject the Oncomouse patent, the 
government of Canada established the “BIOTECanada” biotechnology advisory committee, 
whose conclusion was that the Canadian denial of the Oncomouse patent or the patenting of any 
higher life forms would slow scientific advances, especially in creating transgenic animals 
(Check, 2002).  
In August 2000, the Canadian Federal Court of Appeal decided to grant the Oncomouse 
patent by a vote of two to one, declaring that Oncomouse is a composition of matter.  Justice 
Rothstein concluded that “manufacture” and “composition of matter” should be used more 
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broadly.  Referring to an earlier case where microorganisms were patented, Rothstein used this 
fact to say the Oncomouse should be patented as well. Rothstein also stated that the term 
“invention” includes objects that use the laws of nature, and certainly the construction of 
Oncomouse used “laws of nature” (molecular biology tools) for its creation. 
 However, in October 2000, the Evangelical fellowship intervened, taking the case to the 
Supreme Court of Canada.  On December 5, 2002, for case file number 28155, the Supreme 
Court voted 5 to 4 to not award a patent for the Oncomouse, stating that a mouse even with 
genetic modification is not considered an invention under the Federal Patent Act of 1869 
(Mitchell and Somerville, 2002). In the Canadian Federal Patent Act, the word invention is 
defined as “any new and useful art, process, machine, manufacture or composition of matter, or 
any new and useful improvement in any art, process, machine, manufacture or composition of 
matter”, and the Supreme Court decided the words “manufacture” and “composition” did not 
include higher life forms.  The word “manufacture” denotes a non-living, mechanistic product or 
process, so the mouse can not be considered a “manufacture”.  It also is not a “composition of 
matter”.  Justice Michael Bastarache spoke for the majority of the 5-4 vote, saying "Just as 
‘machine’ and ‘manufacture’ do not imply a living creature, the words ‘composition of matter’ 
are best read as not including higher life forms" (Ching, 2003).   
Even though the Canadian Supreme Court decided against patenting Oncomouse based 
on a strict interpretation of their existing Canada Patent Act, the Judges mentioned that this issue 
must eventually be thought through more broadly (Mitchell and Somerville, 2002).  
  
  
Animal Patenting Followup 
 As of the 21
st
 of September 2003, there were approximately 454 animal patents issued in 
United States (American Anti-Vivisection Society, 2006). Over a fourth of these patents were 
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funded by federal research, and many required putting a human gene in the animal.  54% of these 
patented animals serve as disease models, while the rest serve as bioreactors, drug screening 
models, or for general research (American Anti-Vivisection Society, 2006).   
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PROJECT CONCLUSIONS 
 
 
 
This IQP gives an overview of the complex technology of transgenic animals and how 
the technology relates to society.  It comprises of four chapters that explain 1) the cloning of the 
desired transgene DNA, implanting it in a host, and screening transgenic positives; 2) the 
different applications of transgenic technology, 3) ethical issues and 4) the laws governing 
transgenic patents.   Chapter-1 discusses the two main ways of making transgenic animals, by 
manipulating the pronuclei of fertilized eggs or by manipulating embryonic stem cells.  Both 
methods require prior cloning of the gene of interest (transgene), which is done through 
polymerase chain reaction (PCR), and then the transgene is inserted into a vector, such as a virus 
or plasmid, that helps amplify the DNA.  Many embryos are wasted in the process of creating a 
transgenic animal, making this technology inefficient.  To test whether the animal truly has the 
transgene inserted into their genome, Southern blots or PCR can be used to screen the animals. 
There are about five main categories of transgenic animals created to date:  disease 
models, transpharmers, xenotransplanters, food sources, and biological models.  Disease models 
are transgenic animals that mimic a human disease.  These models are highly useful for 
understanding disease processes and for screening potential therapies, but activists say that some 
models cause animal suffering.  This is true only to an extent, as some types of disease models, 
such as the Alzheimer’s mouse, do not suffer by any measurable criterion.  On the other hand, 
the Oncomouse is a good example where the animal can suffer, but the use of regular painkillers, 
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and euthanizing the animal prior to tumor formation can help minimize animal suffering.  
Transpharmers are animals bred to produce a desired human protein in their milk, blood, or eggs.  
These animals serve as useful bioreactors, with no measurable animal suffering.  Biological 
models are animals engineered to over-express or under-express a specific protein to study its 
effects in vivo.  Xenotransplanters are engineered to create organs for transplant into humans 
while on the waitlist for an organ transplant, an idea that animal welfare groups do not agree 
with.  However, the life-saving benefits to society in this case appear to outweigh the sacrifice of 
the animals.  The most unaccepted type of transgenic animal are food sources, as the public is 
especially in fear of genetically modified foods, in spite the fact that the public has been 
consuming genetic hybrids (plants and animals) for centuries (although those were created by 
selective breeding).  The first transgenic food source created were the transgenic Superpigs 
which was a failed experiment, with the animals suffering serious side effects, so we agree with a 
moratorium on any mammalian growth hormone experiments. However, the transgenic Superfish 
appear to suffer no such side effects, and Aquabounty’s product is near to receiving FDA 
approval.  
Like all very novel sciences that seem to have so much potential, there are many 
ethical issues with creating these animals.  In essence, we must weigh the benefits to society 
against the detriment to the animal or environment. In general, the authors of his IQP agree that 
all categories of transgenic animals should continue, with specific exclusions such as mammalian 
growth hormone experiments, but with strong oversight to minimize animal suffering.    
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Laws have been created to allow the patenting of transgenic animals.  The first life 
form patented was Chakrabarty’s Pseudomonas bacterium engineered to digest oil, for use in 
cleaning up oil spills. The award of this patent paved the way for the first patent issued to an 
animal, Harvard and Dupont’s Oncomouse which is predisposed to cancer.  However, not every 
country allows patenting of animals, Canada currently does not allow patenting of any animals. 
Based on the research performed for this project, the authors feel that we should allow 
most practices of transgenesis, while some should be done with more precaution like the making 
of transgenic food sources, while others should be outright banned such as mammalian growth 
hormone experiments.  With respect to animal patenting, if it helps a company to advance 
medical information, it should be allowed, but without the use of extremely high licensing fees 
which can hinder the smaller labs from using the animals.  Overall, we believe that this 
technology has the potential to save millions of lives and so this type of study should be 
encouraged worldwide with strong oversight. 
 
 
 
